Abstract
Radiopharmaceuticals can provide unique information for drug development also in cardiovascular applications. Radiopharmaceuticals offer possibility to study noninvasively cardiac perfusion, oxygen consumption, oxidative and substrate metabolism, myocardial efficiency of work, neural actions and receptors, vascular inflammation, and molecular processes which all are relevant to understand the effects of drugs. Using these surrogate end points, hypotheses can be tested in vivo in phase I and II clinical studies before starting large-scale clinical phase III or IV trials. In addition, these approaches may allow improved selection of drug therapy for a given patient. Modern techniques such as gene therapy technology provide numerous new potential mechanisms of action and targets for drug development. Device therapies and cell therapies are also under rapid development. Molecular imaging has great potential in evaluating these new therapies and selecting the patient populations and monitoring of the effect of therapy.
Keywords: Cardiovascular Drug, Radiopharmaceuticals, vascular inflammation, CARDIAC PERFUSION, METABOLISM, Molecular imaging
Current Pharmaceutical Design
Title: Cardiovascular Drug Development Using Radiopharmaceuticals
Volume: 15 Issue: 9
Author(s): Heikki Ukkonen, Keiichiro Yoshinaga, Jean N. DaSilva, Rob S.B. Beanlands and Juhani Knuuti
Affiliation:
Keywords: Cardiovascular Drug, Radiopharmaceuticals, vascular inflammation, CARDIAC PERFUSION, METABOLISM, Molecular imaging
Abstract: Radiopharmaceuticals can provide unique information for drug development also in cardiovascular applications. Radiopharmaceuticals offer possibility to study noninvasively cardiac perfusion, oxygen consumption, oxidative and substrate metabolism, myocardial efficiency of work, neural actions and receptors, vascular inflammation, and molecular processes which all are relevant to understand the effects of drugs. Using these surrogate end points, hypotheses can be tested in vivo in phase I and II clinical studies before starting large-scale clinical phase III or IV trials. In addition, these approaches may allow improved selection of drug therapy for a given patient. Modern techniques such as gene therapy technology provide numerous new potential mechanisms of action and targets for drug development. Device therapies and cell therapies are also under rapid development. Molecular imaging has great potential in evaluating these new therapies and selecting the patient populations and monitoring of the effect of therapy.
Export Options
About this article
Cite this article as:
Ukkonen Heikki, Yoshinaga Keiichiro, DaSilva N. Jean, Beanlands S.B. Rob and Knuuti Juhani, Cardiovascular Drug Development Using Radiopharmaceuticals, Current Pharmaceutical Design 2009; 15 (9) . https://dx.doi.org/10.2174/138161209787582011
DOI https://dx.doi.org/10.2174/138161209787582011 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The ACE2-Ang-(1-7)-Mas Axis and Cardioprotection
Current Cardiology Reviews Critical Illness in Obstetric Patients: Introduction and Epidemiology
Current Women`s Health Reviews Comparison of Granulomatosis with Polyangiitis Clinical Features in Patients Depending on Involvement or Absence of Kidney Involvement
Current Rheumatology Reviews Phenotypic Characterization of a Family With An In-frame Deletion in the DMD Gene and Variable Penetrance
Current Gene Therapy Oxidative Stress Genes, Antioxidants and Coronary Artery Disease in Type 2 Diabetes Mellitus
Cardiovascular & Hematological Agents in Medicinal Chemistry Pharmacological Potential of Exercise and RAS Vasoactive Peptides for Prevention of Diseases
Current Protein & Peptide Science Targeting the Chemokines in Cardiac Repair
Current Pharmaceutical Design Calcium Ions in Inherited Cardiomyopathies
Medicinal Chemistry Proteomics to Identify Novel Biomarkers and Therapeutic Targets in Cardiovascular Disease
Letters in Drug Design & Discovery Endothelial Dysfunction in Heart Failure: Mechanisms and Therapeutic Approaches
Current Vascular Pharmacology Animal Models Used for the Evaluation of Antiretroviral Therapies
Current HIV Research Therapeutic Application of Endothelial Progenitor Cells for Treatment of Cardiovascular Diseases
Current Stem Cell Research & Therapy Matrix Metalloproteinase Knockout Studies and the Potential Use of Matrix Metalloproteinase Inhibitors in the Rheumatic Diseases
Current Drug Targets - Inflammation & Allergy Pompe Disease: From New Views on Pathophysiology to Innovative Therapeutic Strategies
Current Pharmaceutical Biotechnology The Critical Role of Insulin-Like Growth Factor-1 Isoforms in the Physiopathology of Skeletal Muscle
Current Genomics Green Tea Attenuates Cardiovascular Remodeling and Metabolic Symptoms in High Carbohydrate-Fed Rats
Current Pharmaceutical Biotechnology Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology Arrhythmias and Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design The Mechanism of Dead-in-Bed Syndrome and Other Sudden Unexplained Nocturnal Deaths
Current Diabetes Reviews Testosterone and Cardioprotection Against Myocardial Ischemia
Cardiovascular & Hematological Disorders-Drug Targets